Article

Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα

Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.
The Journal of clinical investigation (Impact Factor: 13.77). 07/2012; 122(8):2955-66. DOI: 10.1172/JCI43354
Source: PubMed

ABSTRACT Mutations that activate the fms-like tyrosine kinase 3 (FLT3) receptor are among the most prevalent mutations in acute myeloid leukemias. The oncogenic role of FLT3 mutants has been attributed to the abnormal activation of several downstream signaling pathways, such as STAT3, STAT5, ERK1/2, and AKT. Here, we discovered that the cyclin-dependent kinase 1 (CDK1) pathway is also affected by internal tandem duplication mutations in FLT3. Moreover, we also identified C/EBPα, a granulopoiesis-promoting transcription factor, as a substrate for CDK1. We further demonstrated that CDK1 phosphorylates C/EBPα on serine 21, which inhibits its differentiation-inducing function. Importantly, we found that inhibition of CDK1 activity relieves the differentiation block in cell lines with mutated FLT3 as well as in primary patient-derived peripheral blood samples. Clinical trials with CDK1 inhibitors are currently under way for various malignancies. Our data strongly suggest that targeting the CDK1 pathway might be applied in the treatment of FLT3ITD mutant leukemias, especially those resistant to FLT3 inhibitor therapies.

Download full-text

Full-text

Available from: Hanna Radomska, Sep 05, 2015
0 Followers
 · 
128 Views
 · 
53 Downloads
  • Source
    • "However, only 39% of FLT3-ITD AML patients displayed ERK activation, thus suggesting that seemingly there are other mechanisms responsible for Ser 21 phosphorylation of CEBPA. Thus, it was recently reported that cyclin-dependent kinase 1 (CDK1) is an FLT3-ITD-activated kinase, which is responsible for CEBPA phosphorylation on serine 21 and the blocking of its function [68]. Importantly, inhibition of CDK1 activity relieves the differentiation block in cell lines with mutated FLT3, as well as in primary patient-derived leukemic blast samples [68]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of the genetic studies on acute myeloid leukemias (AMLs) has led to the identification of some recurrent genetic abnormalities. Their discovery was of fundamental importance not only for a better understanding of the molecular pathogenesis of AMLs, but also for the identification of new therapeutic targets. In this context, it is essential to identify AML-associated "driver" mutations, which have a causative role in leukemogenesis. Evidences accumulated during the last years indicate that activating internal tandem duplication mutations in FLT3 (FLT3-ITD), detected in about 20% of AMLs, represents driver mutations and valid therapeutic targets in AMLs. Furthermore, the screening of FLT3-ITD mutations has also considerably helped to improve the identification of more accurate prognostic criteria and of the therapeutic selection of patients.
    07/2013; 2013:275760. DOI:10.1155/2013/275760
  • Source
    • "A common theme is the acquisition of self-renewal promoting activity through the ability of these receptors and fusion proteins to activate signal transduction especially the PI3 Kinase (discussed below) and JAK/STAT pathways. The molecular mechanisms still need further elaboration, but possible target genes include HIF2α and HoxA9, and the down regulation of C/EBPα [12,13]. Emerging evidence indicates that not only do the LSCs strongly rely on the BM niche for their self-renewal and proliferation, but they may also modify it to their advantage. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through transcriptional networks. Key activators/regulators of self-renewal include chemokines, cytokines and morphogens which are expressed in the bone marrow niche, either in a paracrine or autocrine fashion, and modulate stem cell behaviour. Increasing evidence suggests that the downstream signaling pathways induced by these ligands converge at multiple levels providing a degree of redundancy in steady state hematopoiesis. Here we will focus on how these pathways cross-talk to regulate HSC self-renewal highlighting potential therapeutic windows which could be targeted to prevent leukemic stem cell self-renewal in myeloid malignancies.
    Cell Communication and Signaling 05/2013; 11(1):33. DOI:10.1186/1478-811X-11-33 · 4.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The interaction between the receptor Flt3 and its ligand FL leads to crucial signalling during the early stages of the commitment of haematopoietic stem cells. Mutation or over-expression of the flt3 gene, leading to constitutive signalling, enhance the survival and expansion of a variety of leukaemias and is associated with an unfavourable clinical outcome for acute myeloid leukaemia (AML) patients. In this study, we used a murine cellular model for AML and primary leukaemic cells from AML patients to investigate the molecular mechanisms underlying the regulation of flt3 gene expression and identify its key cis- and trans-regulators. By assessing DNA accessibility and epigenetic markings, we defined regulatory domains in the flt3 promoter and first intron. These elements permit in vivo binding of several AML-related transcription factors, including the proto-oncogene MYB and the CCAAT/enhancer binding protein C/EBPα, which are recruited to the flt3 promoter and intronic module, respectively. Substantiating their relevance to the human disease, our analysis of gene expression profiling arrays from AML patients uncovered significant correlations between FLT3 expression level and that of MYB and CEBPA. The latter relationship permits discrimination between patients with CEBPA mono- and bi-allelic mutations, and thus connects two major prognostic factors for AML.Leukemia accepted article preview online, 23 January 2013; doi:10.1038/leu.2013.23.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 01/2013; 27(7). DOI:10.1038/leu.2013.23 · 9.38 Impact Factor
Show more